Hematopoietic Stem Cell Epigenetic Reprogramming for Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for enhancing engraftment of hematopoietic stem cells (HSCs) in hematopoietic stem cell transplantation (HSCT) are limited, particularly in cord blood units with low HSC content, and often require the use of cytokines that can lead to lineage commitment rather than expansion of long-term HSCs.
Innovation Solution
A method involving short-term culture (12-36 hours) of HSCs in a media lacking stem cell factor (SCF) and thrombopoietin (TPO), but containing a TGFß agonist, a bioactive phospholipid, an aryl hydrocarbon receptor (AhR) agonist, and a histone deacetylase (HDAC) inhibitor, to enhance engraftment and promote the conversion of HSCs to long-term hematopoietic stem cells (LT-HSCs).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peripheral blood HSCs are used for HSCT, then patient outcomes are improved (decreased relapse rate, improved disease-free survival), but the risk of developing chronic graft versus host disease increases
Solution Approach 1:
The invention changes the functional state of HSCs by treating them with compounds that modulate epigenetic markers (histone acetylation, DNA methylation) and chromatin structure, transforming them from a differentiated state back to a more primitive, less reactive state that resembles cord blood HSCs, thereby reducing GVHD risk while maintaining engraftment benefits
2Object-affected harmful factors
If cord blood HSCs are used for HSCT, then the incidence of graft versus host disease is reduced and greater HLA mismatch is allowed, but the limited amounts of available cord blood HSCs restrict this approach
Solution Approach 1:
The invention performs preliminary action by treating peripheral blood HSCs with epigenetic modulators before transplantation to pre-condition them with properties similar to cord blood HSCs, including reduced T-cell reactivity and enhanced engraftment capacity, thereby achieving cord blood-like benefits without relying on limited cord blood supplies
Solution Approach 2:
The invention creates a functional copy of cord blood HSC properties in peripheral blood HSCs through epigenetic reprogramming, replicating the immunomodulatory and engraftment characteristics of cord blood cells without requiring actual cord blood sources
3Quantity of substance
If culture systems are used to expand CD34+HSCs, then the available HSC numbers are increased, but the use of certain cytokines can lead to lineage commitment rather than expansion of long-term HSCs
Solution Approach 1:
The invention changes the chemical parameters of the culture system by replacing traditional cytokine-based expansion methods with small molecule compounds that target epigenetic mechanisms, thereby expanding HSC numbers while maintaining their undifferentiated, long-term repopulating potential through modulation of histone acetylation and DNA methylation states
Data Source
AI summary
Methods for enhancing engraftment of hematopoictic stem cells (HSCs) (e.g., human CD34+HSCs) in a subject are provided in which the HSCs are cultured prior to transplantation under conditions that enhance engrafiment following transplantation.